We work on drug discovery and development throughout multiple indication areas, using medicinal and bioanalytical chemistry, and link this to clinical practice.

Most of our research focuses on early drug development, based on our expertise in synthetic and bioanalytical chemistry, with a unique pharmaceutical perspective.
In collaboration with other relevant groups, we

  • discover and validate disease-relevant biomarkers;
  • accelerate the discovery of novel tool compounds and drugs for unmet medicinal needs;
  • advance in vitro and ex vivo technologies for improved in vivo predictability in cell and tissue studies;
  • enable tools and strategies for early drug development.



We develop new drug candidates, targets and biomarkers for better diagnosis and treatment

Through our work on early drug development, we want to promote personalized medicine. In order to achieve this we need to bridge the gap from fundamental research to the clinic and industry.

Our research groups collaborate extensively to reach these goals. We also promote cooperation with other relevant groups in the UMCG and FSE, especially in the area of respiratory and cancer research, through joint projects that improve clinical impact and provide better and personalized diagnosis and treatment options for patients.

  • We established spin-off companies (Telesis BV, SMIO BV, NEWCO BV)
  • We raise funds for the UMCG Cancer Research Fund: e.g. Bedumer Winterloop 2016,
  • We develop multi component reaction chemistry for high throughput synthesis of new drug candidates, serving as a starting point for drug testing clinical studies
  • We accelerate early drug discovery through automated and miniaturized nano high throughput synthesis 
  • We developed an organ-on-a-chip microfluidics device allowing high-throughput drug testing using human tissue and cell lines
  • We develop new screening methods to assess pharmacokinetics and activity of biologicals (protein drugs).
  • Discovering tumor and background mutation profiles for each patient is important to understand the molecular mechanisms of tumor development and to find an efficient treatment for individual patient. Proteogenomics data integration is a bioinformatics approach that aims to assess the effect of somatic mutations (obtained during cancer development) and germline mutations (inherited from parents) using genetic or transcriptomics data on proteins. Proteins fulfil biological active molecular functions and are drug targets, therefore proteogenomics provide critical information on the pathways and proteins that should be targeted for efficient cancer treatment.

    We are developing proteogenomics data integration solutions and apply them in various oncological areas (head and neck and ovarian cancers and melanoma) and to respiratory diseases such as COPD.

  • Automation and artificial intelligence (AI) are changing the nature of work. Together, automation and miniaturization are needed in development and production, to speed-up prototype development and decrease time-to-market and stay competitive in a global world. The credo ‘Automation + Miniaturization = Acceleration’ is successfully applied in many technologies and research areas, however not in synthetic chemistry.

    We are developing a technology platform that aims to autonomously discover and optimize early drug candidates. We use methods of automated high throughput nano synthesis, and screening controlled by artificial intelligence. For this we are collating with leading European synchrotrons to determine ligand receptor interactions in a high throughput mode.